0000899243-20-019869.txt : 20200721 0000899243-20-019869.hdr.sgml : 20200721 20200721193542 ACCESSION NUMBER: 0000899243-20-019869 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200717 FILED AS OF DATE: 20200721 DATE AS OF CHANGE: 20200721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kakkar Rahul CENTRAL INDEX KEY: 0001817416 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39381 FILM NUMBER: 201039940 MAIL ADDRESS: STREET 1: C/O PANDION THERAPEUTICS, INC. STREET 2: 134 COOLIDGE AVE., 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pandion Therapeutics, Inc. CENTRAL INDEX KEY: 0001807901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833015614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 134 COOLIDGE AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-393-5925 MAIL ADDRESS: STREET 1: 134 COOLIDGE AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Pandion Therapeutics Holdco LLC DATE OF NAME CHANGE: 20200327 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-17 0 0001807901 Pandion Therapeutics, Inc. PAND 0001817416 Kakkar Rahul C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE WATERTOWN MA 02472 1 1 0 0 Chief Executive Officer Common Stock 2020-07-21 4 C 0 21133 A 702515 I By Shah-Kakkar Holdings, LLC Common Stock 2020-07-21 4 P 0 14000 18.00 A 14000 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 27181 0.00 A 2030-07-16 Common Stock 27181 27181 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 221067 0.00 A 2030-07-16 Common Stock 221067 221067 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 100493 0.00 A 2030-07-16 Common Stock 100493 100493 D Series B Preferred Stock 2020-07-21 4 C 0 107768 0.00 D Common Stock 21133 0 I By Shah-Kakkar Holdings, LLC The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 5, 2020, with the remainder of the shares vesting in equal monthly installments following August 5, 2020 through August 5, 2023, subject to the reporting person's continued service on each applicable vesting date. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date. /s/ Edward Freedman, as attorney-in-fact for Rahul Kakkar 2020-07-21